Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
41
ABUS Quote, Financials, Valuation and Earnings
Last price:
$4.43
Seasonality move
:
19.24%
Day range:
$4.31 - $4.45
52-week range:
$2.71 - $5.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
57.86x
P/B ratio:
10.98x
Volume:
730.5K
Avg. volume:
1.1M
1-year change:
21.76%
Market cap:
$850.1M
Revenue:
$6.2M
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingArbutus Biopharma Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.64, Arbutus Biopharma Corp. has an estimated upside of 27.57% from its current price of $4.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.93 representing 100% downside risk from its current price of $4.42.
Fair Value
-
According to the consensus of 2 analysts, Arbutus Biopharma Corp. has 27.57% upside to fair value with a price target of $5.64 per share.
ABUS vs. S&P 500
-
Over the past 5 trading days, Arbutus Biopharma Corp. has underperformed the S&P 500 by -0.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arbutus Biopharma Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arbutus Biopharma Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Arbutus Biopharma Corp. reported revenues of $529K.
Earnings Growth
-
Arbutus Biopharma Corp. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Arbutus Biopharma Corp. reported earnings per share of -$0.04.
Enterprise value:
761M
EV / Invested capital:
9.28x
Price / LTM sales:
57.86x
EV / EBIT:
--
EV / Revenue:
52.10x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-16.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$13.9M
Return On Assets:
-35.82%
Net Income Margin (TTM):
-289.45%
Return On Equity:
-47.63%
Return On Invested Capital:
-44.8%
Operating Margin:
-1567.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $22.2M | $6.7M | $14.6M | $1.3M | $529K | |
| Gross Profit | $20.9M | $5.3M | $13.9M | $1M | $518K | |
| Operating Income | -$78.5M | -$78.5M | -$31.4M | -$17.5M | -$8.3M | |
| EBITDA | -$77.1M | -$77.1M | -$30.7M | -$17.1M | -$8.3M | |
| Diluted EPS | -$0.47 | -$0.43 | -$0.22 | -$0.10 | -$0.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $126.5M | $141.1M | $141.6M | $132.8M | $97.4M | |
| Total Assets | $165.6M | $203.8M | $158.6M | $140.4M | $97.7M | |
| Current Liabilities | $10.1M | $27.5M | $22.3M | $18.9M | $5.2M | |
| Total Liabilities | $35.5M | $58.3M | $39.3M | $33.6M | $20.3M | |
| Total Equity | $130.1M | $145.5M | $119.3M | $106.9M | $77.4M | |
| Total Debt | $20.2M | $14.3M | $9.6M | $6.3M | $4.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$84.8M | -$70.5M | -$44.7M | -$20.8M | -$5.8M | |
| Cash From Investing | $42.9M | $31.1M | $30.2M | -$11.9M | -$10.3M | |
| Cash From Financing | $37.1M | $53.8M | $4.7M | $1.9M | $847K | |
| Free Cash Flow | -$85.9M | -$70.6M | -$44.8M | -$20.8M | -$5.8M | |
ABUS
Sector
Market Cap
$850.1M
$28.5M
Price % of 52-Week High
86.67%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.47%
-1.33%
1-Year Price Total Return
21.76%
-20.32%
Beta (5-Year)
0.656
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.35
200-day SMA
Buy
Level
$3.70
Bollinger Bands (100)
Buy
Level
3.57 - 4.59
Chaikin Money Flow
Sell
Level
-495.3M
20-day SMA
Sell
Level
$4.43
Relative Strength Index (RSI14)
Buy
Level
50.60
ADX Line
Sell
Level
16.31
Williams %R
Neutral
Level
-43.3239
50-day SMA
Sell
Level
$4.44
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
337.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.1491)
Sell
CA Score
(Annual)
Level (-1.6469)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (3.7161)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Stock Forecast FAQ
In the current month, ABUS has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABUS average analyst price target in the past 3 months is $5.64.
-
Where Will Arbutus Biopharma Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arbutus Biopharma Corp. share price will rise to $5.64 per share over the next 12 months.
-
What Do Analysts Say About Arbutus Biopharma Corp.?
Analysts are divided on their view about Arbutus Biopharma Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arbutus Biopharma Corp. is a Sell and believe this share price will drop from its current level to $4.93.
-
What Is Arbutus Biopharma Corp.'s Price Target?
The price target for Arbutus Biopharma Corp. over the next 1-year time period is forecast to be $5.64 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABUS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arbutus Biopharma Corp. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABUS?
You can purchase shares of Arbutus Biopharma Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arbutus Biopharma Corp. shares.
-
What Is The Arbutus Biopharma Corp. Share Price Today?
Arbutus Biopharma Corp. was last trading at $4.43 per share. This represents the most recent stock quote for Arbutus Biopharma Corp.. Yesterday, Arbutus Biopharma Corp. closed at $4.42 per share.
-
How To Buy Arbutus Biopharma Corp. Stock Online?
In order to purchase Arbutus Biopharma Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABUS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABUS
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
10.98x
1.83x
Price / LTM sales
57.86x
1.60x
Growth Metrics
ABUS
Sector
Revenue growth
-60.49%
4.85%
Earnings growth
61.27%
11.11%
Revenue (5-year growth)
0.53%
6.45%
Earnings forecast
-$0.03
-$0.20
Profitability
ABUS
Sector
Profitability FY 2024
$4.8M
$3.6M
Return on invested capital
-44.8%
-30.98%
Return on assets
-35.82%
-27.62%
Return on equity
-47.63%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
12
Balance Sheet
ABUS
Sector
Total cash
$93.7M
$27.2M
Short term investments
$86.3M
$25.7M
Total assets
$131.7M
$79.7M
Long term debt
$4.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
